Overview |
bsm-33219M-APC-Cy5.5 |
PI3K p85 (5C11) Monoclonal Antibody, APC-Cy5.5 Conjugated |
WB, IF(IHC-P) |
Human, Mouse, Rat, Chicken |
Specifications |
APC-Cy5.5 |
Mouse |
Recombinant mouse PI3K p85 Protein |
1-110/724 |
Monoclonal |
5C11 |
IgG |
1ug/ul |
Purified by Protein G. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
18708 |
P26450 |
Phosphatidylinositol 3-kinase regulatory subunit alpha; Pik3r1; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase subunit p85-alpha; PtdIns-3-kinase regulatory subunit p85-alpha |
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (By similarity). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348926). |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |